Developing new pharmaceuticals entails a long period of over 10 years, as well as a diverse process ranging from basic research to marketing. To free patients from concerns over their illness as soon as possible, we must improve the efficiency of our R&D process. To this end, Santen conducts drug discovery and clinical development on a global basis, utilizing facilities of the Santen Group and related organizations worldwide. In this way, we are reinforcing our system to create new products that meet global medical needs in a timely manner.
In terms of research activities, within Santen we have concentrated our basic research, non-clinical studies, and drug formulation research at Nara Research and Development Center, so as to integrate the knowledge of our various sections and create better products. We are also working to speed up our decision-making. With external organizations, we have built a system to facilitate information exchange and collaborations through our own networks. In 2011, Santen purchased Santen S.A.S. (formally known as Novagali), a French ophthalmic pharmaceutical company that has excellent R&D capability and drug formulation technologies in the dry eye field. This purchase has reinforced Santen's development pipelines, enhancing its international competitiveness in the ophthalmic field.
To speed up clinical development, Santen has relocated its hub to the United States (Santen Inc.), where clinical trials can be conducted in a relatively short time. To improve the quality and efficiency of clinical development, we are building a system to conduct early-stage clinical development in the United States, while conducting the late-stage clinical development in Japan, the United States, Europe, China and other Asian countries, as well as in other emerging countries.
Santen's core interest is ophthalmology. We are focused on corneal disorders that lack effective treatment options and on glaucoma and retinal disorders that are increasing in prevalence due to the aging of society. Our proprietary drug discovery program is also targeting the development of antibiotic compounds as well as other systemic ophthalmic treatments.
Rheumatoid arthritis is another therapeutic interest for Santen. We have gained vast knowledge and experience in the fundamental research on immunosuppression in the course of developing Rimatil (Bucillamine) as an anti-rheumatic treatment. We intend to leverage this experience to carve out a unique position in the pharmaceutical industry in both the ophthalmic and anti-rheumatic fields. Further, we are planning to accelerate drug discovery by combining our fundamental research capabilities for the rapid screening of a vast library of compounds.
We are also expanding our genomic drug discovery, a field at the forefront of modern life science. Through information exchange and joint study efforts with renowned genomic drug discovery external research institutes, we are committed to discovering new breakthroughs in the treatment of eye disorders and rheumatoid arthritis.
|Domain||Corneal and conjunctival disorders||Glaucoma and ocular hypertension||Retinal / uveal disorders||Ocular infections / allergies||Rheumatoid arthritis||Santen S.A.S. product development|
|Disorder||Corneal and conjunctival epithelial disorders||Glaucoma||Diabetic macular edema||Bacterial conjunctivitis||Rheumatoid arthritis||
|Persistent corneal epithelial defects||Uveitis||Allergic conjunctivitis|
New drug discovery begins with screening compounds in a search for promising drug candidates. In our pursuit of compounds that achieve a differentiated therapeutic benefit, Santen has conceived a method called "network-based drug discovery" that complements our in-house screening efforts. Network-based drug discovery fortifies our 120-plus years of scientific knowledge and drug formulation technology experience with the advanced technical achievements held by other firms and research institutes. This method effectively merges external resources with Santen's vast repository of screening models to facilitate the discovery of potentially beneficial compounds and greatly expedite the search process.
Network-based drug discovery is also a powerful tool in the joint development of our proprietary compounds. One successful example is Tafluprost, a prostaglandin analogue for glaucoma and ocular hypertension that became the first Santen product to be released simultaneously across the world. The development of this compound was born from the symbiosis between the Asahi Glass Company's expertise in fluorine compound synthesis and Santen's state-of-the-art screening technology(*1). Both firms received the 2010 Japan Society of Synthetic Organic Chemistry Award for Technical Excellence for this innovation.
Santen is also in engaged in product life-cycle management(*2) aimed at making effective use of existing compounds. Examples include: development of drug delivery systems (DDS) that can sustain therapeutic concentrations over longer periods of time; the application of formulation techniques to expand indications for current products; and efforts to increase the variety of dispensing forms, administration methods, and available doses for the purpose of providing a wider range of treatment options to both health care professionals and patients.
To promote our network-based drug discovery and global R&D efforts, Santen is placing significant emphasis on strengthening our relationships with universities, research organizations and other pharmaceutical firms to conceive new treatments for patients around the world. We hope such relationships will lead to the discovery and launch of novel therapies for severe dry eye syndrome, glaucoma, diabetic macular edema and uveitis, a condition with limited treatment options.
Santen discloses the information on the ongoing clinical studies to confirm safety and efficacy of our drugs on the websites as below.